Chuyển sang chế độ ngoại tuyến với ứng dụng Player FM !
Clinical implementation of PARPi monotherapy for prostate cancer patients – a US and EU perspective
Manage episode 355475862 series 3293376
COR2ED Medical Education: Dr Neal Shore, Uro-Oncologist and Chief Medical Officer for Genesis Care and Urology and Surgical Oncology in the United States and Dr Elena Castro, Medical Oncologist at Hospital Universitario 12 de Octubre in Madrid, discuss clinical implementation of PARP inhibitor monotherapy for prostate cancer patients, providing both a US and EU perspective.
In this podcast, the experts discuss the key efficacy and safety findings from the olaparib registration study, PROfound, and the TRITON-2 study which led to accelerated approval for rucaparib. They also discuss the recent data from the rucaparib confirmatory phase 3 trial, TRITON 3 and based on the results of these studies, debate are all PARP inhibitors the same and can the results be extrapolated from one PARP inhibitor to another.
The timing of treatment with PARP inhibitors versus taxanes is also explored.
Genetic testing is amongst the topics covered, including when to consider germline versus somatic testing and the impact of various homologous recombination repair alterations on efficacy.
87 tập
Manage episode 355475862 series 3293376
COR2ED Medical Education: Dr Neal Shore, Uro-Oncologist and Chief Medical Officer for Genesis Care and Urology and Surgical Oncology in the United States and Dr Elena Castro, Medical Oncologist at Hospital Universitario 12 de Octubre in Madrid, discuss clinical implementation of PARP inhibitor monotherapy for prostate cancer patients, providing both a US and EU perspective.
In this podcast, the experts discuss the key efficacy and safety findings from the olaparib registration study, PROfound, and the TRITON-2 study which led to accelerated approval for rucaparib. They also discuss the recent data from the rucaparib confirmatory phase 3 trial, TRITON 3 and based on the results of these studies, debate are all PARP inhibitors the same and can the results be extrapolated from one PARP inhibitor to another.
The timing of treatment with PARP inhibitors versus taxanes is also explored.
Genetic testing is amongst the topics covered, including when to consider germline versus somatic testing and the impact of various homologous recombination repair alterations on efficacy.
87 tập
Tất cả các tập
×Chào mừng bạn đến với Player FM!
Player FM đang quét trang web để tìm các podcast chất lượng cao cho bạn thưởng thức ngay bây giờ. Đây là ứng dụng podcast tốt nhất và hoạt động trên Android, iPhone và web. Đăng ký để đồng bộ các theo dõi trên tất cả thiết bị.